Ticker: AVBP

ArriVent BioPharma, Inc. (NASDAQ: AVBP) - Snapshot Short take: the company is ramping clinical and discovery programs (primarily firmonertinib), funding the build with public raises and an ATM program while burning cash rapidly. Clinical interim data are encouraging; the income statement shows he...

ARRIVENT BIOPHARMA, INC. (NASDAQ: AVBP) has released its quarterly report for the period ending March 31, 2025. The company is focused on advancing innovative treatments for cancer with its lead candidate, firmonertinib. Positive Aspects: Strong Cash Position: As of March 31, 2025, Arrivent had ...